Stay updated on Nivolumab Plus Ipilimumab Regimens in Melanoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab Regimens in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Plus Ipilimumab Regimens in Melanoma Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-12T14:44:48.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the previous content with an access-denied message and site footer to indicate restricted access to the study record.
    Difference
    0.5%
    Check dated 2026-09-28T16:46:28.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the expected study details with a standard error screen and site footer.
    Difference
    18%
    Check dated 2026-09-21T20:34:41.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    The study overview no longer displays the condition 'Melanoma' and the related topic links (MedlinePlus Genetics), reducing visibility of the disease context and related resources on the page.
    Difference
    0.2%
    Check dated 2026-09-07T20:56:47.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    The page now includes Melanoma as a topic and related topics such as MedlinePlus Genetics, and the revision tag has been updated from v3.6.5 to v3.6.6. This updates contextual metadata and navigation references without altering the study data or outcomes.
    Difference
    0.2%
    Check dated 2026-08-31T17:48:02.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Summary
    An NIH funding annotation, “2016 ( U.S. NIH Grant/Contract ),” was added to the study's identifying numbers. This connects the grant/contract information with the existing identifiers for the trial.
    Difference
    0.1%
    Check dated 2026-08-24T16:35:50.000Z thumbnail image

Stay in the know with updates to Nivolumab Plus Ipilimumab Regimens in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab Regimens in Melanoma Clinical Trial page.